We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

52 hedge funds and large institutions have $7.5M invested in Navidea Biopharmaceuticals Inc. in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 10

0% more funds holding

Funds holding: 52 → 52 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

14% less capital invested

Capital invested by funds: $8.72M → $7.5M (-$1.22M)

30% less call options, than puts

Call options by funds: $30K | Put options by funds: $43K

Holders
52
Holders Change
–
Holders Change %
0%
% of All Funds
1.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
14
Reduced
10
Closed
2
Calls
$30K
Puts
$43K
Net Calls
-$13K
Net Calls Change
+$38K

Top Buyers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
+$125K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$120K
3
Jane Street
Jane Street
New York
+$47.5K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$39.8K
5
TRCT
Tower Research Capital (TRC)
New York
+$24.3K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$325K
2
Millennium Management
Millennium Management
New York
-$102K
3
SIM
Spark Investment Management
New York
-$69.5K
4
Goldman Sachs
Goldman Sachs
New York
-$23.6K
5
SFS
Sowell Financial Services
Arkansas
-$22K
Name Holding Trade Value Shares
Change 		Change in
Stake
SW
26
SVB Wealth
Massachusetts
$24K – – –
Tudor Investment Corp
27
Tudor Investment Corp
Connecticut
$24K – – –
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$22K -$18.2K -1,842 -46%
Bank of America
29
Bank of America
North Carolina
$22K +$8.13K +822 +62%
Wells Fargo
30
Wells Fargo
California
$20K -$494 -50 -2%
Cambridge Investment Research Advisors
31
Cambridge Investment Research Advisors
Iowa
$17K +$30 +3 +0.2%
Commonwealth Equity Services
32
Commonwealth Equity Services
Massachusetts
$16K -$989 -100 -6%
Citadel Advisors
33
Citadel Advisors
Florida
$16K +$573 +58 +4%
LFG
34
LifePlan Financial Group
Ohio
$15K – – –
UBS Group
35
UBS Group
Switzerland
$13K +$6.44K +651 +118%
Group One Trading
36
Group One Trading
Illinois
$12K +$8.04K +813 +201%
SIAS
37
Shine Investment Advisory Services
Colorado
$10K – – –
JCM
38
Jacobi Capital Management
Pennsylvania
$10K +$69 +7 +0.7%
LA
39
Lynch & Associates
Indiana
$9K – – –
RJA
40
Raymond James & Associates
Florida
$8K – – –
Wolverine Trading
41
Wolverine Trading
Illinois
$8K +$7.68K +777 New
Ameriprise
42
Ameriprise
Minnesota
$7K – – –
B
43
Bailard
California
$5K – – –
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$5K +$10 +1 +0.2%
IA
45
IFP Advisors
Florida
$3K – – –
ASN
46
Advisory Services Network
Georgia
$3K +$1.98K +200 +400%
AG
47
Advisor Group
Arizona
$2K – – –
AC
48
Alexandria Capital
Virginia
$1K – – –
Citigroup
49
Citigroup
New York
$1K – – –
MFW
50
Mosaic Family Wealth
Missouri
$1K – – –
1
2
3

NAVB Hedge Fund Activity: Q2 2017 in Review

52 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q2 2017, worth a combined $7.5M — down 14% from $8.72M a quarter earlier.

Fund positioning in NAVB was balanced in Q2 2017: 2 funds opened new positions, 2 closed out, 14 added to existing stakes and 10 trimmed.

The largest buyer was Virtu KCG Holdings, adding an estimated $125K. The largest seller was BlackRock, cutting an estimated $325K.

  • 52 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q2 2017, unchanged from Q1 2017.
  • Funds reported $7.5M of Navidea Biopharmaceuticals Inc. stock for Q2 2017, down 14% quarter-over-quarter.
  • 2 funds opened new Navidea Biopharmaceuticals Inc. positions in Q2 2017 and 2 closed out, a net change of 0 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q2 2017 was Virtu KCG Holdings, an estimated $125K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q2 2017 was BlackRock, an estimated $325K sold.

Based on aggregated 13F filings for Q2 2017.